Skip to main content

Advertisement

Table 2 Subgroup analysis of the relationship between PLR and OS, PFS, DFS, and CSS in UC

From: Prognostic significance of platelet-to-lymphocyte ratio in urothelial carcinoma patients: a meta-analysis

FactorsNo. of
studies
Effect modelHR (95%CI)pHeterogeneity
I2(%)Ph
OS
 All9Random1.23 (0.95–1.59)0.12470.70.001
Sample size
 ≤2006Random1.37 (0.87–2.15)0.17478.7<0.001
 >2003     
Tumor type
 UTUC3Random1.47 (0.70–3.12)0.30980.20.006
 BC6Fixed1.002 (1.000–1.004)0.04936.10.166
Treatment
 RC4Random1.27 (0.83–1.95)0.26656.80.074
 RNU2Fixed2.13 (1.48–3.07)<0.00147.60.167
 TURB2Fixed0.95 (0.74–1.22)0.66600.409
 NUx10.66 (0.32–1.35)0.253
PFS
 All7Random1.81 (1.28–2.56)0.00160.10.020
Sample size
 ≤2004Random1.92 (1.14–3.26)0.015580.067
 >2003Random1.68 (1.03–2.75)0.04060.10.020
Tumor type
 UTUC6Random1.67 (1.2–2.31)0.00254.80.050
 BC14.09 (1.52–11.03)0.005
DFS
 All6Fixed1.69 (1.31–2.16)<0.0010.60.412
Sample size
 ≤2003Fixed1.35 (0.94–1.95)0.10300.573
 >2003Fixed2.05 (1.45–2.90)<0.00100.535
Tumor type
 UTUC5Fixed1.54 (1.17–2.02)0.00200.672
 BC12.74 (1.46–5.14)0.002
Treatment
 RNU4Fixed1.54 (1.17–2.04)0.00200.504
 TURB12.74 (1.46–5.14)0.002
 NUx11.50 (0.47–4.80)0.499
CSS
 All5Fixed1.000 (0.998–1.002)0.91900.859
Sample size
 ≤2002Fixed1.000 (0.998–1.002)0.92300.635
 >2003Fixed1.23 (0.82–1.85)0.31100.968
Tumor type
 UTUC11.20 (0.37–3.86)0.757
 BC4Fixed1.000 (0.998–1.002)0.91900.748
Treatment
 RC2Fixed1.000 (0.998–1.002)0.92300.635
 TURB2Fixed1.24 (0.80–1.91)0.33400.801
 NUx11.20 (0.37–3.86)0.757